Abstract
BackgroundSmall-cell lung cancer (SCLC) remains an extremely challenging disease to treat. Systemic chemotherapy with platinum, etoposide, and PD-L1 inhibitor is the standard of care first-line therapy for extensive stage disease....
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
